Samsung BioLogics Co Ltd

207940: XKRX (KOR)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|K>&$CpLOCK|zQ?$bLOCK|<VVR>KL

Samsung Biologics: Initiating at KRW 1,700,000 on the Back of Margin Expansion and Robust Backlog

We initiate coverage on Samsung Biologics with a Narrow-Moat and Medium Uncertainty Rating at KRW 1,700,000 fair value estimate, which reflects a 16% upside based on the May 7 closing price.

Sponsor Center